How have CYTO shares performed in 2024?

Altamira Therapeutics' stock was trading at $3.48 at the start of the year. Since then, CYTO stock has decreased by 57.2% and is now trading at $1.49. View the best growth stocks for 2024 here .

Are investors shorting Altamira Therapeutics?

Altamira Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 444,500 shares, an increase of 620.4% from the March 15th total of 61,700 shares. Based on an average trading volume of 1,140,000 shares, the days-to-cover ratio is currently 0.4 days. Approximately 28.1% of the shares of the company are short sold. View Altamira Therapeutics' Short Interest .

When is Altamira Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 10th 2024. View our CYTO earnings forecast .

When did Altamira Therapeutics' stock split?

Shares of Altamira Therapeutics reverse split on the morning of Wednesday, December 13th 2023. The 1-20 reverse split was announced on Wednesday, December 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Altamira Therapeutics?

Shares of CYTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CYTO

Altamira Therapeutics (CYTO) Stock Price, News & Analysis

→ This company has increased its dividend every year for 54 years (From DTI) (Ad)

Free CYTO Stock Alerts

$1.44

-0.06 (-4.01%)

(As of 01:34 PM ET)

Compare

Today's Range: $1.43
▼
$1.50
50-Day Range: $1.48
▼
$2.43
52-Week Range: $1.42
▼
$28.40

Volume: 20,871 shs
Average Volume: 989,949 shs
Market Capitalization: $2.27 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Headlines Ownership SEC Filings Short Interest Social Media

Get Altamira Therapeutics alerts:

Ad Tips4Traders

Uncover this 2024 Hidden Gem

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

[Click here to subscribe] and elevate your trading today.

About Altamira Therapeutics Stock (NASDAQ:CYTO)

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.

CYTO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CYTO Stock News Headlines

April 15, 2024 | finance.yahoo.com

Diamond Equity Research Initiates Coverage on Altamira Therapeutics Ltd. (NASDAQ: CYTO)

April 12, 2024 | seekingalpha.com

Altamira Therapeutics Ltd. (CYTO) Q4 2023 Earnings Call Transcript

April 19, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 12, 2024 | msn.com

Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q4 2023 Earnings Call Transcript

April 10, 2024 | finance.yahoo.com

Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results

April 4, 2024 | globenewswire.com

Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024

March 26, 2024 | finanznachrichten.de

Altamira Therapeutics Ltd: Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines

March 26, 2024 | markets.businessinsider.com

Crude Oil Moves Higher; US New Home Sales Fall In February

April 19, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 25, 2024 | msn.com

Why Altamira Therapeutics Stock Is Racing Higher

March 25, 2024 | msn.com

Altamira stock rallies 44% on Univercells mRNA collaboration

March 25, 2024 | globenewswire.com

Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines

February 7, 2024 | finance.yahoo.com

Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal

January 24, 2024 | marketwatch.com

Altamira Therapeutics Shares Rise 13% After Filing Second Provisional Patent Application

January 24, 2024 | msn.com

Altamira Therapeutics stock jumps 7% as it files for second patent

January 24, 2024 | finance.yahoo.com

Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment

January 8, 2024 | finance.yahoo.com

Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit

December 29, 2023 | finance.yahoo.com

Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

December 11, 2023 | msn.com

Altamira shares sink over 40% on corporate, stock split updates

December 11, 2023 | msn.com

Why Altamira Therapeutics (CYTO) Stock Is Down 50% Today

December 11, 2023 | finance.yahoo.com

Altamira Therapeutics Provides Investor and Business Update

December 5, 2023 | finance.yahoo.com

Altamira Therapeutics to Host Investor & Business Update Call on December 11th

December 5, 2023 | finance.yahoo.com

Altamira Therapeutics to Host Investor & Business Update Call on December 11th

December 5, 2023 | benzinga.com

Thinking about buying stock in Macy's Inc, Altamira Therapeutics, Neurosense Therapeutics, Cytosorbents, or Designer Brands?

November 29, 2023 | finance.yahoo.com

Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

November 20, 2023 | uk.finance.yahoo.com

November 17, 2023 | msn.com

Altamira stock surges after deal to sell 51% stake in Medica

See More Headlines

Receive CYTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Altamira Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Next Earnings (Estimated): 7/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CYTO
CUSIP: N/A
CIK: 1601936
Web: www.aurismedical.com
Phone: (441) 295-5950
Fax: 41-61-201-1351
Employees: 10
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.38
Quick Ratio: 1.38

Sales & Book Value

Annual Sales: $320,000.00
Price / Sales: 7.11
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.56 per share
Price / Book: 0.32

Miscellaneous

Outstanding Shares: 1,580,000
Free Float: 1,372,000
Market Cap: $2.28 million
Optionable: Not Optionable
Beta: 1.79

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Thomas Meyer Ph.D. (Age 56)
Founder, President, Chairman, CEO & MD
Comp: $552.7k
Dr. Covadonga Paneda (Age 50)
Chief Operating Officer
Dr. Samuel A. Wickline M.D. (Age 71)
Chief Scientific Adviser

Key Competitors

View All Competitors

CYTO Stock Analysis - Frequently Asked Questions

How have CYTO shares performed in 2024?: Altamira Therapeutics' stock was trading at $3.48 at the start of the year. Since then, CYTO stock has decreased by 57.2% and is now trading at $1.49.
View the best growth stocks for 2024 here.
Are investors shorting Altamira Therapeutics?: Altamira Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 444,500 shares, an increase of 620.4% from the March 15th total of 61,700 shares. Based on an average trading volume of 1,140,000 shares, the days-to-cover ratio is currently 0.4 days. Approximately 28.1% of the shares of the company are short sold.
View Altamira Therapeutics' Short Interest.
When is Altamira Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 10th 2024.
View our CYTO earnings forecast.

When did Altamira Therapeutics' stock split?: Shares of Altamira Therapeutics reverse split on the morning of Wednesday, December 13th 2023. The 1-20 reverse split was announced on Wednesday, December 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
How do I buy shares of Altamira Therapeutics?: Shares of CYTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CYTO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial